All articles by
Chiesi secures Health Canada’s approval for Myalepta in lipodystrophy
Myalepta is indicated as a replacement therapy as an adjunct to diet to treat the complications of leptin deficiency in lipodystrophy patients of age 12 years and older
Novartis to buy German cancer drug developer MorphoSys for €2.7bn
The acquisition is expected to further expand and complement Novartis’ oncology pipeline while helping the firm to develop next-generation oncology treatments and expand its global presence in haematology
Valneva Announces Sale of Priority Review Voucher for $103m
With this approval, IXCHIQ became the world’s first licensed chikungunya vaccine available to address this unmet medical need
Alexion’s Phase 3 Japanese trial results of acoramidis show consistency with ATTRibute-CM trial
The results from the Japanese trial were on par with the ATTRibute-CM trial in terms of survival rates, cardiac-associated hospitalisations, and improvements in functional and quality of life measures
Eton Pharmaceuticals launches Nitisinone capsules to treat hereditary tyrosinemia type 1
Nitisinone capsules are exclusively available through Optime Care, a specialised pharmacy committed to assisting patients dealing with rare diseases in effectively managing their conditions
Lipocine Announces Continued Commercialization of TLANDO through Verity Pharmaceuticals
TLANDO is approved by the FDA as a testosterone replacement therapy
WellSky taps Google Cloud to integrate Generative AI into its solutions
WellSky will use Google Cloud’s secure cloud technologies, advanced data analytics tools, machine learning capabilities, and its enterprise-ready AI platform, Vertex AI, to build and deploy custom generative AI tools within its solutions
UCI Health to acquire Tenet Healthcare’s Pacific Coast Network for $975m
The deal involves Fountain Valley Regional Hospital, Lakewood Regional Medical Center, Los Alamitos Medical, Placentia-Linda Hospital, and other related operations
Biosyngen Announces FDA Fast Track Designation for BST02 in Treatment of Liver Cancer
BST02 has received approval from the FDA for Phase I/II clinical trial in October 2023 and has also been approved by the Center for Drug Evaluation (CDE) of the China National Drug Administration in January, 2024
Graviton Bioscience Announces Strategic Investment from Sanofi to Advance Development of the Next Generation of Selective ROCK2 Inhibitors
Sanofi to receive a 12-month right of first negotiation (ROFN) to explore collaboration opportunities spanning multiple indications, including immunological and metabolic syndrome indications